NFKB1 and gastric cancer: MiRNAs can not only be used as biomarkers of gastric cancer, but also affect Akt and Akt, NF-κB, RAGE, ARF6, TCF4, STAT3 and other signaling pathways promote or inhibit the occurrence and development of gastric cancer [69, 70, 73–76].